Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + pomalidomide + dexamethasone in first-relapse multiple myeloma after prior lenalidomide and proteasome inhibitor
2021-004917-38Phase 2Active
- Sponsor
- Hellenic Society of Hematology
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Primary endpoint: Overall response rate at 6 months. Started May 2022; status: active.
02
Drugs
isatuximabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-004917-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004917-38.